Remedy of Kind 2 Diabetes with IC7Fc Designer Cytokine
Danaei, G. et al. Nationwide, regional and international traits in fasting blood glucose and diabetes prevalence since 1980: systematic evaluation of well being surveys and epidemiological research in 370 international locations and a couple of.7 million contributors. Lancet 378, 31-40 (2011).
Wild, S., G. Roglic, A. Inexperienced, Sicree, R. and King, H. International Prevalence of Diabetes: Estimates for 2000 and Projections for 2030. Diabetes Care 27, 1047-1053 (2004).
Carey, A. L. et al. Interleukin-6 will increase the elimination of insulin-stimulated glucose in people, in addition to the glucose uptake and oxidation of fatty acids in people. in vitro through the activated protein kinase by AMP. Diabetes 55, 2688-2697 (2006).
Watt, M.J. et al. The CNTF reverses obesity-induced insulin resistance by activating AMPK in skeletal muscle. Nat. Med. 12, 541-548 (2006).
Steinberg, G.R. et al. Ciliary neurotrophic issue suppresses hypothalamic signaling of AMP kinase in overweight mice proof against leptin. Endocrinology 147, 3906-3914 (2006).
Matthews, V.B. et al. Mice poor in interleukin-6 develop hepatic irritation and systemic resistance to insulin. Diabetologia 53, 2431-2441 (2010).
ACTS. A double-blind, placebo-controlled medical trial of subcutaneous recombinant human ciliary neurotrophic issue (rHCNTF) in amyotrophic lateral sclerosis. Research Group on the Remedy of ALS CNTF Neurology 46, 1244-1249 (1996).
Duff, E. & Baile, C. A. Ciliary neurotrophic issue: a job in weight problems? Nutr. Rev. 61, 423-426 (2003).
Ettinger, M. P. et al. Recombinant variant of ciliary neurotrophic issue for weight reduction in overweight adults: a randomized examine as much as the dosage. Jam. Med. Assoc. 289, 1826-1832 (2003).
Febbraio, M. A. Function of Interleukins in Weight problems: Implications for Metabolic Ailments. Endocrinol Tendencies. Metab. 25, 312-319 (2014).
Kraakman, M.J. et al. Blocking the retransmission of IL-6 prevents the recruitment of macrophages into adipose tissue induced by a high-fat weight loss program, however doesn’t enhance insulin resistance. Cell Metab. 21, 403-416 (2015).
Rabe, B. et al. The transgenic blockage of interleukin 6 transmitted by the sign suppresses irritation. Blood 111, 1021-1028 (2008).
Febbraio, M.A. gp130 receptor ligands as potential therapeutic targets for weight problems. J. Clin. Make investments. 117, 841-849 (2007).
Kallen, Okay.J. et al. Cytokine receptor recognition websites are organized into exchangeable modules. Switch of receptor binding website of leukemia inhibitory issue ciliary neurotrophic issue to interleukin-6. J. Biol. Chem. 274, 11859-1387 (1999).
Rakemann, T. et al. The hyper-interleukin-6 designer cytokine is a potent activator of STAT3-dependent gene transcription in vivo and in vitro. J. Biol. Chem. 274, 1257-1266 (1999).
Harris, J. M. and Chess, R. B. Impact of pegylation on prescribed drugs. Nat. Rev. Drug Discov. 2, 214-221 (2003).
Jazayeri, J. A. and Carroll, G. J. Fc-based cytokines: Prospects for superior therapeutics. BioDrugs 22, 11-26 (2008).
Srikanthan, P. & Karlamangla, A.S. Relative muscle mass is inversely related to insulin and prediabetes resistance. Outcomes of the Third Survey on the Nationwide Well being and Diet Examination. J. Clin. Endocrinol. Metab. 96, 2898-2903 (2011).
Taniguchi, Okay. et al. A gp130-Src-YAP module connects irritation to epithelial regeneration. Nature 519, 57-62 (2015).
Watt, Okay.I. et al. The YAP effector of the hippopotamus pathway is a necessary regulator of skeletal muscle fiber measurement. Nat. Frequent. 6, 6048 (2015).
Grey, Mechanisms and implications of skeletal fragility induced by A. Thiazolidinedione. Overweight diabetics. Metab. 11, 275-284 (2009).
Mannaerts, I. et al. The YAP effector of the Hippo pathway controls the activation of hepatic stellate cells of the mouse. J. Hepatol. 63, 679-688 (2015).
Ellingsgaard, H. et al. Interleukin-6 will increase insulin secretion by rising the secretion of glucagon-like peptide-1 from L-cells and alpha-cells. Nat. Med. 17, 1481-1489 (2011).
Scheidt-Nave, C. et al. Serum interleukin 6 is a serious predictor of bone loss in girls particular to menopause in the course of the first decade. J. Clin. Endocrinol. Metab. 86, 2032-2042 (2001).
Whitham, M. & Febbraio, M. A. The Myokinoma Constantly Increasing: Challenges to Discovery and Therapeutic Implications. Nat. Rev. Drug Discov. 15, 719-729 (2016).
Tibble, C.A., Cavaiola, T.S. & Henry, R.R. Longer-acting GLP-1 receptor agonists and potential for bettering cardiovascular outcomes: evaluate of present literature. Professional Rev. Endocrinol. Metab. eight, 247-259 (2013).
Glaesner, W. et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab. Res. Rev. 26, 287-296 (2010).
Nauck, M. et al. Efficacy and security of dulaglutide versus sitagliptin after 52 weeks of therapy for sort 2 diabetes in a randomized managed trial (AWARD-5). Diabetes Care 37, 2149-2158 (2014).
Larsson, L. et al. Sarcopenia: lack of muscle mass and performance associated to ageing. Physiol. Rev. 99, 427-511 (2019).
Ma, C., Tonks, Okay.T., Heart, J.R., Samocha-Bonet, D. and Greenfield, J.R. Advanced interplay between adiposity, insulin resistance, and bone well being. Clin. Obes. eight, 131-139 (2018).
Xie, D. et al. Transgenic mice overexpressing the glucose-dependent insulinotropic peptide have elevated bone mass. Bone 40, 1352-1360 (2007).
Askmyr, M. et al. Ciliary neurotrophic issue has intrinsic and extrinsic roles within the regulation of B cell differentiation and bone construction. Sci. Rep. 5, 15529 (2015).
Hezareh, M., Hessell, AJ, Jensen, RC, Winkel van, JG & Parren, PW Actions of the effector operate of a bunch of mutants of a largely neutralizing antibody towards the virus of the illness. human immunodeficiency sort 1. J. Virol. 75, 12161-12168 (2001).
Schmittgen, T.D. & Livak, Okay. J. Analyze real-time PCR information with the assistance of
T. Nat. Protocols three, 1101-1108 (2008).
Chen, Z. P. et al. Impact of depth of train on AMPK signaling in skeletal muscle in people. Diabetes 52, 2205-2222 (2003).
Henstridge, D.C. et al. Genetic manipulation of cardiac Hsp72 ranges doesn’t alter the metabolism of the substrate, however helps to raised perceive the resistance to cardiac insulin brought on by a excessive fats weight loss program. Cell Stress Chaperones 20, 461-472 (2015).
Jordy, A.B. et al. Hepatic lipidoma evaluation reveals protecting results of bodily exercise on hepatosteatosis induced by a high-fat weight loss program in mice. A m. J. Physiol. Endocrinol. Metab. 308, E778 to E791 (2015).
Kowalski, G. M. et al. Overexpression of sphingosine kinase 1 within the liver diminished the triglyceride content material in mice fed a low however not excessive fats weight loss program. Biochim. Biophys. Acta 1851, 210-219 (2015).
Brandon, A.E. et al. Suppression of protein kinase C epsilon in adipose tissue, however not within the liver, improves glucose tolerance. Cell Metab. 29, 183-191.e7 (2019).
Hansotia, T. et al. DIRKO mice (double incretin receptor knockout) reveal a necessary position of the enteric axis within the transduction of glucoregulatory actions of DPP-IV inhibitors. Diabetes 53, 1326-1335 (2004).
Pal, M. et al. The impairment of JNK-1 signaling in skeletal muscle doesn’t have an effect on glucose homeostasis and insulin resistance related to weight problems in mice. PLoS ONE eight, e54247 (2013).